Expression patterns of bcr-abl measured by real-time quantitative PCR in patients with chronic myeloid leukemia during treatment with imatinib mesylate
10.3760/cma.j.issn.1009-9921.2009.11.007
- VernacularTitle:实时定量聚合酶链反应监测慢性粒细胞白血病患者接受伊马替尼治疗期间bcr-abl融合基因拷贝数的变化
- Author:
Xiaodan WANG
;
Yanli LI
;
Lin QIU
;
Runzhang LU
;
Hong LIANG
;
Tiejun GONG
;
Wenpeng HAO
;
Jun MA
- Publication Type:Journal Article
- Keywords:
Leukemia;
myeloid;
chronic;
Poly merase chain reaction;
Fusion proteins;
ber-abl;
Imatinib mesylate
- From:
Journal of Leukemia & Lymphoma
2009;18(11):659-662
- CountryChina
- Language:Chinese
-
Abstract:
Objective To monitor the expression patterns of bcr-abl in chronic myeloid leukemia (CML) patients during treatment with imatinib mesylate and evaluate the detection of MRD by RQ-PCR method. Methods The ABI Prism 7500 Sequence Detection System using Taqman fluorogenic probes was used to quantify target gene. bcr-abl mRNA was detected by RQ-PCR in 106 CML patients. The normalized quotient (NQ) of bcr-abl mRNA was calculated as followings: NQ=bcr-abl mRNA copy numbers/abl mRNA copy numbers. Results The NQ of BCR-ABL mRNA was well correlated with the progression of disease and the number of Ph+ cell (r =0.9824 and 0.9346, respectively). The NQ was decreased rapidly in 62 patients and kept in low level for a long time, and only 2 of them were relapsed. For 8 patients, after treatment the NQwere decreased initially and increased sharply, 7 of them were relapsed after 5-9 months. After treatment the NQ of 31 patients were still>0.1, 11 patients were relapsed after a short remission and 7 were ineffective or progression. Out of 5 patients whose NQ were fluctuated and had little regularity, but all of them had a continuing remission. Conclusion RQ-PCR is a more sensitive technique in the detection of bcr-abl fusion gene.It is an important method to monitor the tumor cell during the treatment with imatinib mesylate in CML patients.
